Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Specific peptide interference reveals BCL6 transcriptional and oncogenic mechanisms in B-cell lymphoma cells.

Nature medicine - 1 Dec 2004

Polo Jose M, Dell'Oso Tania, Ranuncolo Stella Maris, Cerchietti Leandro, Beck David, Da Silva Gustavo F, Prive Gilbert G, Licht Jonathan D, Melnick Ari

Abstract excerpt

The BTB/POZ transcriptional repressor and candidate oncogene BCL6 is frequently misregulated in B-cell lymphomas. The interface through which the BCL6 BTB domain mediates recruitment of the SMRT, NCoR and BCoR corepressors was recently identified. To determine the contribution of this interface to BCL6 transcriptional and biological properties, we generated a peptide that specifically binds BCL6 and blocks...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Amino Acid Motifs
Share to B-Lymphocytes

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Fluorescent Antibody Technique

Share to Genes, Regulator

Share to Immunoprecipitation

Share to Lymphoma, Large B-Cell, Diffuse

Share to Peptides

Share to Proto-Oncogene Proteins c-bcl-6

Source

Identifiers

PMID: 15531890
DOI: 10.1038/nm1134

Genes

BCL6

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Specific peptide interference reveals BCL6 transcriptional and oncogenic mechanisms in B-cell lymphoma cells.PMID 15531890Read ↗

A peptomimetic inhibitor of BCL6 with potent antilymphoma effects in vitro and in vivoSemantic proximity Read ↗

Therapeutic targeting of the BCL6 oncogene for diffuse large B-cell lymphomasSemantic proximity Read ↗

Structure of a BCOR corepressor peptide in complex with the BCL6 BTB domain dimer.Semantic proximity Read ↗

BCL6 as a therapeutic target for lymphoma.Semantic proximity Read ↗

Progress toward B-Cell Lymphoma 6 BTB Domain Inhibitors for the Treatment of Diffuse Large B-Cell Lymphoma and BeyondSemantic proximity Read ↗

Molecular Pathogenesis of Non-Hodgkin's Lymphoma: the Role of Bcl-6Semantic proximity Read ↗

The LAZ3/BCL6 oncogene encodes a sequence-specific transcriptional inhibitor: a novel function for the BTB/POZ domain as an autonomous repressing domain.Semantic proximity Read ↗

Critical Residues within the BTB Domain of PLZF and Bcl-6 Modulate Interaction with CorepressorsSemantic proximity Read ↗

Leveraging the BAF chromatin remodeling complex for targeted transcriptional rewiring in cancerSemantic proximity Read ↗

Rewiring Cancer Drivers to Activate ApoptosisSemantic proximity Read ↗

Rationally designed BCL6 inhibitors target activated B cell diffuse large B cell lymphomaSemantic proximity Read ↗

Transient expression of Bcl6 is sufficient for oncogenic function and induction of mature B-cell lymphoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.